Three syndromes, three genes, and the organ clusters that define them
Opening Vignette
A 35-year-old woman presents with kidney stones, fatigue, and constipation. Labs show calcium 11.8 mg/dL and elevated PTH. She also has a history of peptic ulcer disease refractory to PPIs. Her mother had a pituitary adenoma. Which syndrome should be suspected?
A. MEN 2A (Sipple Syndrome)
B. MEN 2B
C. MEN 1 (Wermer Syndrome)
D. Sporadic Primary Hyperparathyroidism
A fails (MEN 2A): MEN 2A is driven by a gain-of-function RET proto-oncogene mutation and produces a triad of medullary thyroid carcinoma, pheochromocytoma, and mild hyperparathyroidism. There is no gastrinoma component in MEN 2A, so no mechanism exists for refractory peptic ulcers , and no pituitary adenomas are part of the syndrome.
B fails (MEN 2B): MEN 2B shares the RET mutation and MTC + pheo with 2A, but adds marfanoid habitus and mucosal neuromas while removing parathyroid involvement entirely. The hypercalcemia and kidney stones in this vignette alone eliminate MEN 2B , it has no parathyroid component whatsoever.
D fails (Sporadic hyperPTH): Sporadic primary hyperparathyroidism is a single-gland disease. It explains hypercalcemia and kidney stones but provides no mechanism for refractory peptic ulcers (which require a gastrin-secreting tumor) or a pituitary adenoma in a first-degree relative. Three organ systems in a familial pattern define a syndrome, not isolated sporadic disease.
C is correct , MEN 1 = The 3 Ps: Parathyroid (hypercalcemia → kidney stones, most common and earliest manifestation), Pancreatic islet tumors (gastrinoma drives Zollinger-Ellison syndrome = refractory ulcers + diarrhea despite PPIs), Pituitary adenoma (prolactinoma most common; mother's history confirms autosomal dominant inheritance). Gene: MEN1, chromosome 11q13, encodes menin (nuclear tumor suppressor, loss-of-function).
Break it down: Hypercalcemia + refractory peptic ulcers + pituitary adenoma with family history = MEN 1 triad. Any option without a gastrinoma mechanism is eliminated.
Section 1 of 5
The Three MEN
Each syndrome has a signature gene and a signature cluster. Know all three cold.
Primary hyperparathyroidism is the most common and earliest manifestation. Causes hypercalcemia, kidney stones, bone pain, constipation, psychosis. Treat FIRST before addressing other tumors.
P2 · Pancreatic Islet Tumors
Gastrinoma is most common (Zollinger-Ellison syndrome: refractory ulcers, diarrhea). Insulinoma is second. Also VIPoma (Verner-Morrison / WDHA), glucagonoma. Usually multiglandular and malignant when found in MEN 1 context.
P3 · Pituitary Adenoma
Prolactinoma is most common (amenorrhea, galactorrhea, decreased libido). Also GH-secreting (acromegaly) and ACTH-secreting (Cushing disease). Bitemporal hemianopia with large adenomas compressing optic chiasm.
Mnemonic"1-1-1: MEN 1 = menin protein = chromosome 11 = three P-organs (Parathyroid, Pancreas, Pituitary)." One number, one gene, one chromosome, three Ps.
Always present. Arises from parafollicular C-cells. Secretes calcitonin (tumor marker, not used for Ca2+ regulation here). CEA is secondary marker. Prophylactic thyroidectomy indicated in all RET-positive patients. Prognosis depends on codon mutation type.
Pheochromocytoma · ~50%
Catecholamine-secreting adrenal medulla tumor. Hypertensive crisis risk. MUST rule out pheo with plasma/urine metanephrines BEFORE any surgery (including thyroidectomy). Bilateral in 50% of MEN 2A cases.
Primary Hyperparathyroidism · 20-30%
Usually mild hypercalcemia. Unlike MEN 1, not the dominant or earliest feature. PTH elevated; may be asymptomatic at diagnosis.
Screening order in RET+ patients: RET gene test first, then calcitonin (MTC), then plasma metanephrines (pheo), then PTH/Ca2+ (hyperPTH). Treat pheo before thyroid surgery.
Mnemonic"2A = 2 mandatory tumors: MTC + Pheo. Parathyroid is optional." Two cancers you cannot miss, one you might get lucky on.
Earliest onset. Most aggressive form of all MEN-associated MTCs. Prophylactic thyroidectomy should occur within the first 6 months of life in confirmed MEN 2B patients.
Pheochromocytoma
Same as MEN 2A. Must test metanephrines before any surgical intervention.
Marfanoid Habitus
Tall stature, long limbs, arachnodactyly, high arched palate. No lens subluxation (distinguishes from true Marfan syndrome). Pectus deformity common.
Mucosal Neuromas · Pathognomonic
Neuromas on lips, tongue, eyelid margins, and GI tract. Ganglioneuromatosis of the bowel causes constipation or diarrhea. Visible lip neuromas are the key physical exam finding that distinguishes 2B from 2A.
No Parathyroid Involvement
Unlike MEN 1 and 2A, hyperparathyroidism does NOT occur in MEN 2B. If you see MEN 2B + hypercalcemia, think another etiology.
Mnemonic"2B = Bodies look different (marfanoid body + mucosal neuromas). No parathyroid. The lips tell the story."
Gene vs. Mechanism: RET = MEN 2A and 2B (proto-oncogene, gain-of-function mutation). MEN1 = MEN 1 (tumor suppressor, loss-of-function). One activates cancer. One removes the brakes.
Section 2 of 5
Tumor Markers & Workup
Know which marker goes with which tumor, and which test to order FIRST.
Critical safety rule: ALWAYS rule out pheochromocytoma BEFORE any surgery in MEN 2A/2B. Operating on an uncontrolled pheochromocytoma triggers a catecholamine storm: hypertensive crisis, arrhythmia, and death. No exceptions.
MEN 1 workup sequence: Calcium and PTH first (parathyroid is the most common manifestation). Then fasting gastrin (ZES). Then MRI pituitary (prolactin, IGF-1). Treat hypercalcemia first before addressing pancreatic or pituitary tumors.
Section 3 of 5
Associated Syndromes
These syndromes arise from specific pancreatic tumors. Know each by its unique cluster.
🔥
Zollinger-Ellison Syndrome (ZES)
Gastrinoma · Refractory Ulcers
⌄
A gastrinoma (usually pancreas or duodenum) secretes excess gastrin, which drives parietal cells to produce massive amounts of HCl. Result: multiple peptic ulcers, often in unusual locations (jejunum, distal duodenum), diarrhea from acid inactivating pancreatic enzymes, and esophagitis.
Diagnosis: Fasting gastrin >1000 pg/mL is diagnostic. In borderline cases (200-1000), use secretin stimulation test: paradoxically INCREASES gastrin in ZES (normal: gastrin falls with secretin). Gastric pH <2 with elevated gastrin confirms autonomous gastrin secretion.
Treatment: High-dose PPI is first-line for symptom control. Surgical resection if sporadic ZES. In MEN 1-associated ZES, treat hyperparathyroidism first (hypercalcemia potentiates gastrin secretion); then consider surgical resection vs. medical management depending on tumor burden.
🌧
VIPoma · Verner-Morrison Syndrome
WDHA · Pancreatic Cholera
⌄
A VIP-secreting pancreatic tumor causes the WDHA triad: Watery Diarrhea (massive secretory, often >3 liters/day, persists with fasting), Hypokalemia (from GI potassium loss), Achlorhydria (VIP inhibits gastric acid, opposite of ZES).
Also called "pancreatic cholera" for the cholera-like volume of watery diarrhea. Key distinguishing point: stool osmolality shows a secretory gap (stool Na/K accounts for most osmolality), and diarrhea persists with fasting (secretory, not osmotic).
A glucagon-secreting alpha-cell tumor of the pancreas. Excess glucagon drives catabolism: it mobilizes amino acids for gluconeogenesis, depletes serum amino acids, and causes the 4 Ds:
Dermatitis · Necrolytic migratory erythema is pathognomonic: painful, pruritic, spreading erythematous rash with central crusting, classically in the groin, perianal area, and lower extremities. Results from hypoaminoacidemia and zinc deficiency.
Depression + weight loss (muscle wasting from excess catabolism)
Diagnosis: Elevated plasma glucagon (>1000 pg/mL), hyperglycemia, hypoaminoacidemia. Treatment: Octreotide + surgical resection. Zinc supplementation may improve the rash.
Section 4 of 5
Elimination Game
Reveal clues one at a time. Each clue eliminates at least one diagnosis. Work until one stands.
A 28-year-old woman presents with amenorrhea, galactorrhea, and headaches. Ophthalmology confirms bitemporal hemianopia. Labs show markedly elevated serum prolactin. RET genetic testing is negative. Her father has a history of recurrent kidney stones and peptic ulcer disease refractory to PPIs.
MEN 1 (Wermer)
MEN 2A (Sipple)
MEN 2B
Sporadic Prolactinoma
Clue 1: RET genetic testing is negative. MEN 2A and MEN 2B both require an activating RET mutation. No RET, no MEN 2. Both are eliminated immediately.
Clue 2: The father has kidney stones (primary hyperparathyroidism) AND peptic ulcer disease refractory to PPIs (gastrinoma / ZE syndrome). Those are two of the three Ps in MEN 1. The patient herself has a pituitary adenoma (third P). This is a familial pattern matching MEN 1, not a sporadic prolactinoma.
Diagnosis Confirmed
MEN 1
All three Ps present across two generations: Parathyroid (father's kidney stones), Pancreas (father's ZE syndrome), Pituitary (patient's prolactinoma). RET negative excluded MEN 2A/2B. Familial pattern excluded sporadic prolactinoma.
Section 5 of 5
Quiz
4 original board-style questions. No peeking.
A 42-year-old man is found to carry a germline RET mutation (codon 634) consistent with MEN 2A. He has calcitonin of 180 pg/mL (elevated) and is scheduled for total thyroidectomy next week. Pre-operative workup is in progress. What must be done before proceeding to the operating room?
ACheck serum calcium and PTH
BObtain a 24-hour urine cortisol
CMeasure plasma or urine metanephrines to rule out pheochromocytoma
DPerform vocal cord assessment via laryngoscopy
Tempting to check calcium and PTH first since hyperparathyroidism is the most common MEN 2A manifestation and the patient is already heading to the OR, but elevated calcium is a manageable post-op problem while an unrecognized pheo will kill the patient during anesthetic induction. Think of the pheo screen as checking for a lit fuse before entering the building: everything else, Ca/PTH, cortisol, cords, can be handled after you confirm the bomb is not armed. A fails (Ca/PTH): Checking calcium and PTH is important for evaluating MEN 2A-associated hyperparathyroidism (~20-30% of patients), but mild hypercalcemia does not carry acute intraoperative mortality risk. If you operate with an uncontrolled pheo, anesthetic induction can trigger a catecholamine surge causing hypertensive crisis, arrhythmia, and cardiac arrest. Hypercalcemia can be addressed after pheo is cleared , there is no coming back from a catecholamine storm.
B fails (urine cortisol): A 24-hour urine cortisol tests for Cushing syndrome, which requires an ACTH-secreting pituitary, adrenal cortex adenoma, or ectopic ACTH source. MEN 2A involves the adrenal medulla (pheochromocytoma), not the adrenal cortex. There is nothing in this vignette suggesting hypercortisolism: no central obesity, striae, moon facies, or proximal myopathy. This test has no indication here.
D fails (laryngoscopy): Pre-operative vocal cord assessment checks recurrent laryngeal nerve function before thyroid surgery , relevant because a pre-existing paresis changes surgical approach. But a paretic cord alters how you operate; an unrecognized pheochromocytoma determines whether you should operate at all. Think of it like checking tire pressure versus checking if there's a bomb in the engine bay.
C is correct: In MEN 2A, pheochromocytoma occurs in ~50% of patients. The adrenal medulla tumor stores and releases massive catecholamines under stress , including surgical stress. Plasma or urine metanephrines must confirm pheo is absent before any anesthetic is given. This is a hard rule with no exceptions in MEN 2A/2B pre-op workup.
Break it down: In MEN 2A heading to the OR: rule out pheo first with metanephrines. Everything else , Ca/PTH, cortisol, cords , is secondary to preventing a fatal catecholamine surge.
A pediatrician examines an 8-year-old boy with a family history of thyroid cancer. On exam, the child has elongated limbs, a marfanoid build, and visible nodules on the lips and anterior tongue. Genetic testing reveals a RET M918T mutation. Which feature is most specific for his diagnosis and distinguishes it from MEN 2A?
AElevated calcitonin
BPheochromocytoma
CMucosal neuromas
DPrimary hyperparathyroidism
Tempting to pick pheochromocytoma since it occurs in roughly 50% of both MEN 2A and MEN 2B patients and is the high-drama shared feature, but the question asks what distinguishes 2B FROM 2A, not what they share. Think of a venn diagram with overlapping circles: pheo lives in the overlap, mucosal neuromas live exclusively in the 2B circle. Only what is outside the overlap can discriminate. A fails (elevated calcitonin): Calcitonin is the tumor marker for medullary thyroid carcinoma (MTC), which arises from calcitonin-secreting parafollicular C-cells. MTC occurs in both MEN 2A and MEN 2B , both are driven by activating RET mutations. An elevated calcitonin confirms MTC is present but tells you nothing about which MEN 2 variant you are looking at.
B fails (pheochromocytoma): Pheochromocytoma occurs in approximately 50% of both MEN 2A and MEN 2B patients , it is a shared feature with no discriminating power between the two variants.
D fails (primary hyperparathyroidism): Hyperparathyroidism is present in MEN 2A (~20-30%) but is absent in MEN 2B. Choosing D gets the logic backwards: finding hyperparathyroidism steers you toward MEN 2A, not away from it. The question asks what distinguishes MEN 2B from 2A , a feature unique to or shared with 2A is the wrong direction.
C is correct: Mucosal neuromas , visible benign nerve sheath tumors on the lips, tongue, and eyelid margins , are pathognomonic for MEN 2B and do not occur in MEN 2A. They arise from ganglioneuromatosis that also affects the bowel (causing constipation or diarrhea). The child's visible lip and tongue nodules are the single exam finding that locks in MEN 2B over 2A. The RET M918T codon mutation (vs. codon 634 in 2A) confirms it genetically.
Break it down: MEN 2A vs. 2B: both have MTC + pheo. 2A adds hyperparathyroidism. 2B adds mucosal neuromas + marfanoid habitus and removes parathyroid. The neuromas are pathognomonic , nothing else is.
A 50-year-old woman has recurrent peptic ulcers despite high-dose PPI therapy and multiple duodenal ulcers on endoscopy. Fasting gastrin is 420 pg/mL (upper limit of normal: 100). To confirm Zollinger-Ellison syndrome, a secretin stimulation test is performed. Which finding confirms the diagnosis?
AGastrin falls by more than 50% after secretin infusion
BGastrin remains unchanged after secretin infusion
CGastrin decreases by 20% then rebounds
DGastrin increases by more than 200 pg/mL after secretin infusion
Tempting to say gastrin stays flat since the autonomous gastrinoma ignores normal feedback signals and "autonomy" sounds like "no change," but autonomous tumors do not simply resist inhibition, they actively fire back when provoked. Think of the gastrinoma as a smoke alarm that has been hardwired into the wrong circuit: when the building sends a silence signal (secretin), the alarm not only keeps going but gets louder. The paradoxical rise is the diagnostic signal. A fails (gastrin falls >50%): Secretin normally suppresses gastrin secretion from antral G-cells through somatostatin intermediaries. A >50% fall in gastrin means the gastrin is coming from feedback-sensitive normal G-cells, not from an autonomous tumor. This response argues strongly against ZES and toward benign causes of mild gastrin elevation: PPI use, atrophic gastritis, or antral G-cell hyperplasia.
B fails (gastrin unchanged): A flat response means the gastrin source is neither suppressed by secretin nor stimulated by it. While an autonomous tumor might escape suppression, ZES does not produce a flat line , it produces a sharp paradoxical rise. No change does not confirm gastrinoma; it is indeterminate at best.
C fails (decreases 20% then rebounds): ZES , Zollinger-Ellison syndrome , occurs when a gastrinoma, a gastrin-secreting tumor of the pancreas or duodenum, secretes gastrin autonomously and drives extreme acid overproduction, causing ulcers in unusual GI locations including the jejunum. The gastrinoma is insulated from normal feedback signals. When secretin is infused, the tumor responds with a rapid, sustained gastrin rise , not an initial dip. A 20%-drop-then-rebound pattern does not match the kinetics of autonomous gastrinoma secretion and is not accepted as diagnostic for ZES by any published criteria.
D is correct: In normal physiology, secretin inhibits gastrin. In ZES, the gastrinoma ignores the inhibitory signal and responds with a paradoxical rise of >200 pg/mL above baseline. Think of it like turning off the music and watching one person in the room keep dancing , normal G-cells go quiet when secretin signals; the gastrinoma keeps firing. This counterintuitive rise is diagnostic.
Break it down: Secretin stimulation test = positive for ZES when gastrin rises >200 pg/mL. A fall argues against ZES (normal response); flat or dip-rebound does not confirm it.
A medical student is asked to name the gene responsible for MEN 1, its chromosomal location, and the protein it encodes. Which of the following is entirely correct?
ARET proto-oncogene, chromosome 10, encodes a receptor tyrosine kinase
BMEN1, chromosome 13, encodes menin
CMEN1, chromosome 11q13, encodes menin (a tumor suppressor)
DMEN1, chromosome 11, encodes a G-protein coupled receptor
Tempting to pick chromosome 13 since 11 and 13 look similar under pressure and both host famous tumor suppressors (RB1 is on 13), but MEN 1 lives on chromosome 11. Lock in the mnemonic: MEN 1 = chromosome 11. One extra digit is all that separates a right answer from a wrong one here. Think of the number as a self-referential address: the disease is named MEN 1, and it lives at chromosome 11. Same first digit, same neighborhood. A fails (RET, chr 10, receptor tyrosine kinase): RET is a proto-oncogene on chromosome 10q11 that encodes a receptor tyrosine kinase, and activating gain-of-function RET mutations cause MEN 2A and MEN 2B. But this question asks about MEN 1, which involves an entirely different gene, chromosome, and mechanism. RET has no role in MEN 1.
B fails (MEN1, chr 13, menin): The gene name (MEN1) and the protein (menin) are correct, but chromosome 13 is wrong. MEN1 sits on chromosome 11q13. Chromosome 13 is home to RB1 (retinoblastoma tumor suppressor) and BRCA2. This is a pure memorization trap: 11 and 13 look similar under pressure. Anchor it: MEN 1 → chromosome 11.
D fails (MEN1, chr 11, GPCR): The gene name and chromosomal location are correct, but menin is not a G-protein coupled receptor. GPCRs are membrane-spanning receptors that activate intracellular second messengers , like the PTH receptor, TSH receptor, or adrenergic receptors. Menin is a nuclear scaffold protein that participates in chromatin remodeling and transcription regulation. The cellular compartment, structure, and function are all different.
C is correct: MEN1 gene → chromosome 11q13 → encodes menin (nuclear scaffold protein, tumor suppressor) → loss-of-function mutations → unchecked proliferation of parathyroid, pancreatic islet, and pituitary cells. Classic two-hit tumor suppressor model: one germline mutation, one somatic hit, brakes are gone.
Break it down: MEN 1 genetics: gene = MEN1, chromosome = 11q13, protein = menin (nuclear tumor suppressor, NOT a kinase or GPCR). RET is MEN 2A/2B only.
A 45-year-old woman with known MEN 2A has a sister who is asymptomatic. Genetic testing reveals the sister carries the same germline RET mutation at codon 634. Baseline calcitonin is 8 pg/mL (normal less than 10). She has no palpable thyroid nodule and no symptoms. What is the most appropriate next step?
AObserve with annual calcitonin measurements until it exceeds 100 pg/mL
BStart external beam radiation to the thyroid to prevent medullary carcinoma
CRecommend prophylactic total thyroidectomy after ruling out pheochromocytoma with plasma metanephrines
DPerform thyroid ultrasound-guided FNA and wait for pathology before deciding on surgery
Tempting to observe with serial calcitonin since the current calcitonin is normal and watchful waiting sounds conservative and responsible, but codon 634 is a high-risk mutation where MTC penetrance approaches 100% and metastasis can precede any biochemical signal. Think of this as a structural fire hazard that has been certified in the building plans: the inspector does not wait for smoke to appear before requiring the renovation. The genetics have already decided the outcome; waiting for a lab value means waiting for established disease. A fails (observe with annual calcitonin): Observation with serial calcitonin is reserved for low-risk RET codon mutations with predictably late and indolent MTC onset. Codon 634 carries a high-risk classification: MTC penetrance approaches 100%, onset occurs in childhood or early adulthood, and the tumor can metastasize before calcitonin rises to 100 pg/mL. Waiting for a biochemical threshold means waiting for established metastatic disease.
B fails (external beam radiation): Radiation therapy has no prophylactic role in MTC. External beam radiation is reserved for locally unresectable or metastatic disease as palliative treatment , it cannot sterilize the C-cells that will produce MTC in a RET carrier. The only way to eliminate the risk is to surgically remove the thyroid tissue those cells inhabit.
D fails (FNA then decide): Fine needle aspiration is the diagnostic tool for differentiated thyroid cancer , papillary and follicular carcinomas , where cytology changes management. For a confirmed RET carrier with a high-risk codon, the genetics have already decided: MTC will develop. Waiting for FNA pathology adds delay without adding information that would change the recommendation. FNA also performs poorly for medullary carcinoma in the pre-invasive phase.
C is correct: In a confirmed RET codon 634 carrier, prophylactic total thyroidectomy is standard. Before any anesthetic, pheochromocytoma must be excluded with plasma metanephrines , MEN 2A pheo occurs in ~50% of patients, and operating on an uncontrolled pheo triggers a catecholamine surge that can be fatal. Once pheo is cleared, surgery proceeds.
Break it down: RET positive + high-risk codon = prophylactic thyroidectomy. Never to the OR without ruling out pheo first with metanephrines.
A 60-year-old woman with a history of kidney stones, fatigue, and confusion is found to have serum calcium of 12.4 mg/dL and PTH of 180 pg/mL. Imaging shows a 1.8 cm parathyroid adenoma. She also has a 1.2 cm pancreatic mass on MRI that is hormonally silent. A germline MEN1 mutation is confirmed. She asks which tumor should be addressed first.
AParathyroid adenoma should be addressed first because hypercalcemia potentiates gastrin secretion and worsens symptoms from any concurrent pancreatic tumors
BThe pancreatic mass should be addressed first because it is the most lethal component of MEN 1
CBoth tumors should be addressed simultaneously in a single operation
DNeither requires surgery since both are small; medical management with cinacalcet is first-line
Tempting to address the pancreatic mass first since pancreatic islet tumors are the most lethal MEN 1 component and the mass sounds more dangerous, but this mass is hormonally silent and creating no immediate harm, while hypercalcemia is actively amplifying gastrin secretion from any concurrent gastrinoma. Think of hypercalcemia as fertilizer for the other MEN 1 tumors: removing the fertilizer first makes everything downstream more manageable before you decide whether the silent mass even needs surgery. B fails (pancreatic mass first): The 1.2 cm pancreatic mass is hormonally silent , it produces no biochemical abnormality and no immediate symptoms. Meanwhile, hypercalcemia from the parathyroid adenoma is actively potentiating gastrin secretion: calcium directly stimulates gastrin release from G-cells and from any concurrent gastrinoma. Treating hyperparathyroidism first removes this stimulus, often improving ZES control and potentially deferring or simplifying the pancreatic decision.
C fails (simultaneous surgery): Combined parathyroid and pancreatic surgery in a single sitting increases operative time, anesthetic exposure, and procedural complexity. Beyond the technical argument, there is a biochemical rationale for sequencing: normalizing calcium first may reduce the size or hormonal output of a concurrent gastrinoma, changing the risk calculus for the pancreatic operation. Guidelines recommend addressing hyperparathyroidism first, not both simultaneously.
D fails (cinacalcet medical management): Cinacalcet is a calcimimetic , it increases the parathyroid cell's sensitivity to extracellular calcium, suppressing PTH release and lowering serum calcium. It is used in patients who are poor surgical candidates or in secondary hyperparathyroidism from chronic kidney disease. For a resectable parathyroid adenoma with clear surgical indications (calcium 12.4, symptomatic with confusion and kidney stones) in a patient without contraindications, cinacalcet controls the lab value without removing the tumor. Surgery is definitive.
A is correct: In MEN 1, treat primary hyperparathyroidism first. Hypercalcemia potentiates gastrin secretion and worsens any concurrent Zollinger-Ellison syndrome. The parathyroid is also the most common and earliest manifestation. After calcium is normalized, assess the pancreatic mass with interval imaging and functional testing before committing to pancreatic surgery.
Break it down: MEN 1 treatment sequence , parathyroid calcium first, then pancreas, then pituitary. Hypercalcemia is not just a symptom; it is a driver of other MEN 1 tumor behavior.
A 30-year-old man with a history of medullary thyroid carcinoma (already treated with total thyroidectomy) now presents with drenching night sweats, headaches, and blood pressure of 210/115 mmHg during clinic triage. His mother had MEN 2A. Urine collection over 24 hours shows markedly elevated normetanephrine levels.
ABegin IV labetalol immediately to control the hypertensive emergency
BOrder CT abdomen to locate the tumor, then schedule surgery for next week
CAdminister IV phentolamine for acute blood pressure control
DStart oral alpha-blockade with phenoxybenzamine or doxazosin first, then add beta-blockade only after adequate alpha-blockade is achieved, then resect after 10-14 days of preparation
Tempting to use IV labetalol since it blocks both alpha and beta and sounds like a balanced dual-blocker for the crisis, but labetalol is 7:1 beta-dominant and blocking the beta receptors first removes the compensatory vasodilation (beta-2) while the alpha-driven vasoconstriction keeps firing unopposed. Think of it like trying to calm a runaway horse by removing the saddle: you just made it harder to control without addressing what is driving it forward. Alpha blockade must tighten the reins before you adjust the equipment. A fails (IV labetalol): Labetalol has both alpha and beta blocking activity, but its beta-to-alpha ratio is approximately 7:1 , the beta component dominates. In pheochromocytoma, catecholamines are already activating alpha receptors (vasoconstriction). If you block beta receptors first while alpha receptors remain stimulated, you eliminate the compensatory vasodilation (beta-2) while the unopposed alpha-driven vasoconstriction continues , potentially worsening the hypertensive crisis rather than controlling it.
B fails (CT then surgery next week without preparation): Localization imaging is necessary, but scheduling surgery one week away without pharmacologic preparation bypasses the physiologic reset that makes the operation survivable. Surgical manipulation of a pheo , retraction, ligation, CO2 insufflation , releases massive catecholamines. Ten to fourteen days of alpha-blockade allows volume repletion (pheo patients are chronically vasoconstricted and volume-depleted) and receptor normalization. One week is not enough; the preparation is not optional.
C fails (IV phentolamine for acute control): Phentolamine is a reversible non-selective alpha-blocker appropriate for managing acute hypertensive crises from catecholamine excess , a short-term emergency tool. The question asks for the overall management strategy leading to definitive surgical resection. The correct answer describes the full pre-operative preparation pathway, not just crisis intervention.
D is correct: The pheo management sequence is rigid: oral alpha-blockade first (phenoxybenzamine or doxazosin) for 10-14 days, then beta-blockade added only after adequate alpha-blockade is established, then surgery. Alpha-first prevents unopposed vasoconstriction if beta receptors are blocked prematurely. The preparation window also allows the patient to become euvolemic before the OR.
Break it down: Pheo prep = alpha first, then beta, then cut. Never beta before alpha. Never surgery without preparation.
A 12-year-old boy is seen for evaluation of visible lumps on his lips and tongue that have been present since infancy. His mother reports he had constipation as a baby. He is tall with long, slender fingers. Ophthalmologic exam is normal. Thyroid ultrasound shows a 1.5 cm hypoechoic nodule. His father died of thyroid cancer at age 28.
AMEN 1 with a prolactinoma and gastrinoma as the likely additional components
BMEN 2A with likely concurrent primary hyperparathyroidism
CMarfan syndrome with coincidental thyroid nodule
DMEN 2B with mucosal neuromas, marfanoid habitus, and high risk for early aggressive medullary thyroid carcinoma
Tempting to call this Marfan syndrome since the marfanoid build, long fingers, and tall stature are textbook Marfan features that every student has memorized, but Marfan syndrome requires lens subluxation (ectopia lentis) which this patient specifically does NOT have, and Marfan does not produce mucosal neuromas or cause early thyroid cancer. Think of the ophthalmologic exam as the fingerprint that separates two look-alikes: normal eyes close the Marfan door completely, and the lip nodules open the MEN 2B door just as completely. A fails (MEN 1 with prolactinoma/gastrinoma): MEN 1 produces the three Ps , Parathyroid, Pancreatic islet tumors, Pituitary adenoma. It does not cause mucosal neuromas, marfanoid habitus, or early aggressive thyroid cancer. The lip and tongue nodules present since infancy cannot be explained by any component of MEN 1.
B fails (MEN 2A with hyperparathyroidism): MEN 2A includes medullary thyroid carcinoma, pheochromocytoma, and hyperparathyroidism (20-30%) , but mucosal neuromas are pathognomonic for MEN 2B and do not occur in MEN 2A. The presence of lip and tongue nodules since infancy is the single finding that distinguishes 2B from 2A and cannot be attributed to 2A regardless of other features.
C fails (Marfan syndrome with coincidental nodule): Marfan syndrome produces marfanoid habitus through fibrillin-1 mutations and typically includes lens subluxation (ectopia lentis), aortic root dilation, and pectus deformity. The ophthalmologic exam here is specifically reported as normal , ruling out the lens subluxation that distinguishes true Marfan from MEN 2B's marfanoid features. Marfan syndrome does not produce mucosal neuromas, and the father's death from thyroid cancer at 28 is not explained by Marfan at all.
D is correct: Mucosal neuromas on the lips and tongue present since infancy, combined with marfanoid habitus (normal ophtho rules out true Marfan), a thyroid nodule, and a father who died of thyroid cancer at 28 = MEN 2B. This child needs urgent RET genetic testing. If confirmed, prophylactic total thyroidectomy within the first 6 months of life is the standard , MEN 2B MTC is the most aggressive of all MEN-associated thyroid cancers.
Break it down: Mucosal neuromas + marfanoid body (no lens subluxation) + thyroid mass + family history of early thyroid cancer = MEN 2B. Neuromas are the pathognomonic exam finding.
Question 1 of 8
0/8
Questions Correct
Board-Style Walkthrough
Board-Style Walkthrough
Original board-style vignettes. Shuffled, never-repeat, full Chicago explanations.